Additional Study Augments the Results of AOBiome's Successful 547 Patient Phase 2b Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis and Moderate-to-Severe Pruritus using its B244 investigational drug

Further investigation supported previous findings on the secondary effects of inert Ammonia Oxidizing Bacteria (AOB), even after it no longer converts ammonia to Nitric Oxide and Nitrite. A recently-published in vitro study has demonstrated that both live and metabolically inactive AOB can downregulate Th2-associated pruritic cytokines. For more details see: https://www.nature.com/articles/s41598-021-93299-1.

The company ran a separate open label 30 subject cosmetic safety study utilizing a cosmetic strength of metabolically inactive (heat-killed) AOB in subjects with itch associated with mild-to-moderate atopic dermatitis. The results of this study bolster the assessment of AOB as it relates to both safety and the positive results seen in the company's 547 patient Phase 2b study with live B244 material and the trailing effect, once that study was completed.

Key results from the separate Cosmetic study:

• No adverse events
• Reductions in itch were seen within the first hour of application
• Itch score improvements were observed in both adult and pediatric subjects throughout the study by VAS (0-10 scale) and Itch Man (0-4 scale), respectively. Mean adult itch scores improved from 6.98±1.78 at Baseline to 3.01±2.22 at Day 14 (57% reduction), and mean pediatric itch scores improved from 2.64±0.67 at Baseline to 0.82±0.75 at Day 14 (69% reduction)
• 57.9% of adult subjects showed a 4-point improvement in itch (Visual Analog Scale) at Day 14 (11-point scale)
• 81.8% of pediatric subjects showed a 2-point improvement in itch (Itch Man Scale) at Day 14 (5-point scale)
• The benefits for itch were sustained, with reductions from Baseline persisting after discontinuation of use – similar to results seen in the Phase 2b study.
• Subjects showed improvement in the appearance of eczema at Day 14 as compared to Baseline.

"These results show that AOB can still have real-world impact on the immune system even when AOB is neither consuming ammonia or no longer viable. This has huge implications for AOB's persistence on the skin, the effectiveness of our clinical products and the simplicity of incorporating AOB into patient's everyday routines." says President & CEO, Todd Krueger.

AOBiome is in the process of planning Phase 3 studies for B244, for which it aims to start recruiting patients in 2023.

AOBiome's B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be well-tolerated in clinical studies to date.

Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. See full article at: https://www.nature.com/articles/s41598-021-93299-1.

AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical therapeutics for inflammatory conditions. AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. Learn more at www.aobiome.com.

Contacts:

For Media Inquiries:
Jim Hoffman
845-417-3487
[email protected] 

SOURCE AOBiome